CME credits: 0.25 Valid until: 31-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/ Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiothera…

CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension …

CME credits: 0.25 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-optimizing-outcomes-in-aad-case-review/26713/ Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD …

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bridging-distances-in-pah-bringing-best-practices-to-the-people-through-telemonitoring/24051/ Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to…

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-cystic-fibrosis-addressing-disparities-challenging-perceptions-and-innovating-patient-centered-care/24487/ Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. …

CME credits: 1.00 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bringing-treatment-into-focus-biomarker-driven-first-line-therapy-for-metastatic-gastricgej-cancers/26719/ This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (G…

CME credits: 0.25 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-copd-from-symptom-recognition-to-emerging-treatment-strategies/26928/ Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and update…

CME credits: 0.75 Valid until: 02-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-met-tkis-in-nsclc/17986/ The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer…

CME credits: 0.25 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-redefining-treatment-across-the-spectrum-of-hrher2-expressing-metastatic-breast-cancer/26625/ This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast ca…

CME credits: 0.25 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/implementing-a-multidisciplinary-approach-to-heart-failure-patient-identification-and-treatment-using-novel-device-therapy/16191/ Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms…

CME credits: 1.00 Valid until: 24-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/noncovalent-btk-inhibitors-new-targeted-options-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/24362/ This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, part…

CME credits: 0.25 Valid until: 18-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-antibody-based-therapies-are-revolutionizing-its-management/26371/ Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innov…

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/level-up-your-skills-tailoring-management-of-hf/27021/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diab…

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/a-practical-guide-to-prescribing-in-hf/27019/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and …

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/partnering-with-patients-building-effective-communication-and-support-in-hf-care/27018/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing ra…

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/earlier-is-better-identifying-and-diagnosing-hf-early-in-disease-progression/27017/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates …

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/hf-management-for-patients-with-comorbid-conditions/27020/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as …

CME credits: 0.50 Valid until: 13-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/targeting-resistance-in-egfrm-nsclc-with-her3-directed-adcs-in-the-community-setting/24489/ The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/significance-of-her2-expression-in-solid-tumors/26788/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapie…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-ovarian-cancer-treatment-landscape/26794/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications f…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical de…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-biliary-tract-cancer-treatment-landscape/26795/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implicat…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-testing-strategies-across-tumor-types-amidst-guidelines-gaps/26789/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and …

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-and-managing-treatment-related-adverse-effects-associated-with-her2-directed-agents/26793/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implication…

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-on-targeting-her2-in-her2-expressing-solid-tumors/26791/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and cli…